Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo
Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo
Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation
Fifty-two week...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Vitiligo